➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Merck
Medtronic
Boehringer Ingelheim
Express Scripts
Johnson and Johnson
AstraZeneca

Last Updated: July 13, 2020

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 204412


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

NDA 204412 describes DELZICOL, which is a drug marketed by Apil and is included in one NDA. It is available from three suppliers. There is one patent protecting this drug and one Paragraph IV challenge. Additional details are available on the DELZICOL profile page.

The generic ingredient in DELZICOL is mesalamine. There are twenty-eight drug master file entries for this compound. Twenty-six suppliers are listed for this compound. Additional details are available on the mesalamine profile page.
Summary for 204412
Tradename:DELZICOL
Applicant:Apil
Ingredient:mesalamine
Patents:1
Formulation / Manufacturing:see details
Pharmacology for NDA: 204412
Medical Subject Heading (MeSH) Categories for 204412
Suppliers and Packaging for NDA: 204412
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
DELZICOL mesalamine CAPSULE, DELAYED RELEASE;ORAL 204412 NDA Allergan, Inc. 0023-5853 0023-5853-18 180 CAPSULE, DELAYED RELEASE in 1 BOTTLE (0023-5853-18)
DELZICOL mesalamine CAPSULE, DELAYED RELEASE;ORAL 204412 NDA A-S Medication Solutions 50090-3002 50090-3002-0 180 CAPSULE, DELAYED RELEASE in 1 BOTTLE (50090-3002-0)
Paragraph IV (Patent) Challenges for 204412
Tradename Dosage Ingredient NDA Submissiondate
DELZICOL CAPSULE, DELAYED RELEASE;ORAL mesalamine 204412 2014-06-17

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:CAPSULE, DELAYED RELEASE;ORALStrength400MG
Approval Date:Feb 1, 2013TE:ABRLD:Yes
Patent:  Start TrialPatent Expiration:Apr 13, 2020Product Flag?YSubstance Flag?Delist Request?

Expired US Patents for NDA 204412

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Apil DELZICOL mesalamine CAPSULE, DELAYED RELEASE;ORAL 204412-001 Feb 1, 2013   Start Trial   Start Trial
Apil DELZICOL mesalamine CAPSULE, DELAYED RELEASE;ORAL 204412-001 Feb 1, 2013   Start Trial   Start Trial
Apil DELZICOL mesalamine CAPSULE, DELAYED RELEASE;ORAL 204412-001 Feb 1, 2013   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Johnson and Johnson
AstraZeneca
McKinsey
McKesson
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.